Cargando…

A RET::GRB2 fusion in pheochromocytoma defies the classic paradigm of RET oncogenic fusions

The RET kinase receptor is a target of mutations in neural crest tumors, including pheochromocytomas, and of oncogenic fusions in epithelial cancers. We report a RET::GRB2 fusion in a pheochromocytoma in which RET, functioning as the upstream partner, retains its kinase domain but loses critical C-t...

Descripción completa

Detalles Bibliográficos
Autores principales: Estrada-Zuniga, Cynthia M., Cheng, Zi-Ming, Ethiraj, Purushoth, Guo, Qianjin, Gonzalez-Cantú, Hector, Adderley, Elaina, Lopez, Hector, Landry, Bethany N., Zainal, Abir, Aronin, Neil, Ding, Yanli, Wang, Xiaojing, Aguiar, Ricardo C.T., Dahia, Patricia L.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381411/
https://www.ncbi.nlm.nih.gov/pubmed/35858593
http://dx.doi.org/10.1016/j.xcrm.2022.100686
Descripción
Sumario:The RET kinase receptor is a target of mutations in neural crest tumors, including pheochromocytomas, and of oncogenic fusions in epithelial cancers. We report a RET::GRB2 fusion in a pheochromocytoma in which RET, functioning as the upstream partner, retains its kinase domain but loses critical C-terminal motifs and is fused to GRB2, a physiological RET interacting protein. RET::GRB2 is an oncogenic driver that leads to constitutive, ligand-independent RET signaling; has transforming capability dependent on RET catalytic function; and is sensitive to RET inhibitors. These observations highlight a new driver event in pheochromocytomas potentially amenable for RET-driven therapy.